XML 37 R28.htm IDEA: XBRL DOCUMENT v3.22.2.2
Collaboration Agreements, License Agreement and Revenues - AstraZeneca Agreements - Additional Information 1 (Detail) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Jul. 30, 2013
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Total revenue   $ 15,735 $ 155,973 $ 106,367 $ 218,766  
Deferred Revenue   7,361   7,361   $ 15,857
Drug product revenue recognized   15,735 155,973 106,367 218,766  
Product Revenue, Net [Member]            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Total revenue   17,359 13,442 59,495 42,175  
Drug product revenue recognized   17,359 13,442 59,495 42,175  
Drug Product Revenue [Member]            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Total revenue   4,077 0 4,610 (168)  
Drug product revenue recognized   4,077 0 $ 4,610 (168)  
AstraZeneca Agreements [Member] | U.S./RoW [Member]            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Upfront, non-contingent, non-refundable and time-based payments $ 1,200,000          
Additional consideration based on net sales description       low 20% range    
Aggregate consideration received excluding drug product revenue   439,000   $ 439,000    
AstraZeneca Agreements [Member] | China [Member]            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Upfront, non-contingent, non-refundable and time-based payments $ 376,700          
Aggregate considerations received       77,200    
Direct Sales [Member] | Product Revenue, Net [Member]            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Total revenue   2,445 3,114 8,622 9,680  
Drug product revenue recognized   $ 2,445 $ 3,114 $ 8,622 $ 9,680